-
1
-
-
84928774156
-
The future of immune checkpoint therapy
-
[PMID: 25838373]
-
Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56-61. [PMID: 25838373] doi:10.1126/science.aaa8172
-
(2015)
Science
, vol.348
, pp. 56-61
-
-
Sharma, P.1
Allison, J.P.2
-
2
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
[PMID: 20525992]
-
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23. [PMID: 20525992] doi:10.1056/NEJMoa1003466
-
(2010)
N Engl J Med.
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
-
3
-
-
84992340907
-
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial
-
[PMID: 27592805]
-
Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374-85. [PMID: 27592805] doi: 10.1016/S1470-2045(16)30364-3
-
(2016)
Lancet Oncol.
, vol.17
, pp. 1374-1385
-
-
Kaufman, H.L.1
Russell, J.2
Hamid, O.3
Bhatia, S.4
Terheyden, P.5
D'Angelo, S.P.6
-
4
-
-
84989918072
-
Safety and efficacy of durvalumab (MEDI4736), an antiprogrammed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer
-
[PMID: 27269937]
-
Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, et al. Safety and efficacy of durvalumab (MEDI4736), an antiprogrammed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016; 34:3119-25. [PMID: 27269937] doi:10.1200/JCO.2016.67.9761
-
(2016)
J Clin Oncol.
, vol.34
, pp. 3119-3125
-
-
Massard, C.1
Gordon, M.S.2
Sharma, S.3
Rafii, S.4
Wainberg, Z.A.5
Luke, J.6
-
5
-
-
84907543029
-
Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)
-
Ribas A, Hodi FS, Kefford R, Hamid O, Daud A, Wolchok JD, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol. 2014;32. doi: 10.1200/jco.2014.32.18-suppl.lba9000
-
(2014)
J Clin Oncol.
, pp. 32
-
-
Ribas, A.1
Hodi, F.S.2
Kefford, R.3
Hamid, O.4
Daud, A.5
Wolchok, J.D.6
-
6
-
-
84925222119
-
Nivolumab in previously untreated melanoma without BRAF mutation
-
[PMID: 25399552]
-
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320-30. [PMID: 25399552] doi:10.1056/NEJMoa1412082
-
(2015)
N Engl J Med.
, vol.372
, pp. 320-330
-
-
Robert, C.1
Long, G.V.2
Brady, B.3
Dutriaux, C.4
Maio, M.5
Mortier, L.6
-
7
-
-
84908354848
-
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial
-
[PMID: 25034862]
-
Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109-17. [PMID: 25034862] doi:10.1016/S0140-6736(14)60958-2
-
(2014)
Lancet
, vol.384
, pp. 1109-1117
-
-
Robert, C.1
Ribas, A.2
Wolchok, J.D.3
Hodi, F.S.4
Hamid, O.5
Kefford, R.6
-
8
-
-
84959577118
-
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A singlearm, multicentre, phase 2 trial
-
[PMID: 26952546]
-
Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a singlearm, multicentre, phase 2 trial. Lancet. 2016;387:1909-20. [PMID: 26952546] doi:10.1016/S0140-6736(16)00561-4
-
(2016)
Lancet
, vol.387
, pp. 1909-1920
-
-
Rosenberg, J.E.1
Hoffman-Censits, J.2
Powles, T.3
Van Der-Heijden, M.S.4
Balar, A.V.5
Necchi, A.6
-
9
-
-
85013634537
-
Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports
-
[PMID: 27472273]
-
Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One. 2016;11: e0160221. [PMID: 27472273] doi:10.1371/journal.pone.0160221
-
(2016)
PLoS One
, vol.11
, pp. e0160221
-
-
Abdel-Wahab, N.1
Shah, M.2
Suarez-Almazor, M.E.3
-
10
-
-
84940746759
-
Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis
-
[PMID: 26337719]
-
Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015; 13:211. [PMID: 26337719] doi:10.1186/s12916-015-0455-8
-
(2015)
BMC Med.
, vol.13
, pp. 211
-
-
Bertrand, A.1
Kostine, M.2
Barnetche, T.3
Truchetet, M.E.4
Schaeverbeke, T.5
-
11
-
-
84965032301
-
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
-
[PMID: 27141885]
-
Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13:473-86. [PMID: 27141885] doi:10.1038/nrclinonc.2016.58
-
(2016)
Nat Rev Clin Oncol.
, vol.13
, pp. 473-486
-
-
Boutros, C.1
Tarhini, A.2
Routier, E.3
Lambotte, O.4
Ladurie, F.L.5
Carbonnel, F.6
-
12
-
-
84962286789
-
Survivorship in immune therapy: Assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center
-
[PMID: 25649350]
-
Johnson DB, Friedman DL, Berry E, Decker I, Ye F, Zhao S, et al. Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center. Cancer Immunol Res. 2015;3:464-9. [PMID: 25649350] doi:10.1158/2326-6066.CIR-14-0217
-
(2015)
Cancer Immunol Res.
, vol.3
, pp. 464-469
-
-
Johnson, D.B.1
Friedman, D.L.2
Berry, E.3
Decker, I.4
Ye, F.5
Zhao, S.6
-
13
-
-
84936147067
-
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
-
[PMID: 26027431]
-
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34. [PMID: 26027431] doi:10.1056/NEJMoa1504030
-
(2015)
N Engl J Med.
, vol.373
, pp. 23-34
-
-
Larkin, J.1
Chiarion-Sileni, V.2
Gonzalez, R.3
Grob, J.J.4
Cowey, C.L.5
Lao, C.D.6
-
14
-
-
84856862354
-
PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer
-
[PMID: 22306905]
-
Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, Hobo W, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 2012;35:169-78. [PMID: 22306905] doi:10.1097/CJI.0b013e318247a4e7
-
(2012)
J Immunother.
, vol.35
, pp. 169-178
-
-
Dulos, J.1
Carven, G.J.2
Van Boxtel, S.J.3
Evers, S.4
Driessen-Engels, L.J.5
Hobo, W.6
-
15
-
-
67649268353
-
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
-
[PMID: 19457253]
-
von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med. 2009;7:35. [PMID: 19457253] doi:10.1186/1479-5876-7-35
-
(2009)
J Transl Med.
, vol.7
, pp. 35
-
-
Von Euw, E.1
Chodon, T.2
Attar, N.3
Jalil, J.4
Koya, R.C.5
Comin-Anduix, B.6
-
16
-
-
84984663113
-
Checkpoint immunotherapy: Good for cancer therapy, bad for rheumatic diseases [Editorial]
-
[PMID: 27566797]
-
Calabrese L, Velcheti V. Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases [Editorial]. Ann Rheum Dis. 2017;76:1-3. [PMID: 27566797] doi:10.1136/annrheumdis-2016-209782
-
(2017)
Ann Rheum Dis.
, vol.76
, pp. 1-3
-
-
Calabrese, L.1
Velcheti, V.2
-
17
-
-
84893965118
-
Immune modulation in cancer with antibodies
-
[PMID: 24188664]
-
Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med. 2014;65:185-202. [PMID: 24188664] doi:10.1146/annurev-med- 092012-112807
-
(2014)
Annu Rev Med.
, vol.65
, pp. 185-202
-
-
Page, D.B.1
Postow, M.A.2
Callahan, M.K.3
Allison, J.P.4
Wolchok, J.D.5
-
18
-
-
34248383514
-
Guidelines for submitting adverse event reports for publication
-
International Society for Pharmacoepidemiology [PMID: 17472416]
-
Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards RI, Fernandez AM, et al; International Society for Pharmacoepidemiology. Guidelines for submitting adverse event reports for publication. Drug Saf. 2007;30:367-73. [PMID: 17472416]
-
(2007)
Drug Saf.
, vol.30
, pp. 367-373
-
-
Kelly, W.N.1
Arellano, F.M.2
Barnes, J.3
Bergman, U.4
Edwards, R.I.5
Fernandez, A.M.6
-
19
-
-
84888248267
-
Melanoma-associated retinopathy treated with ipilimumab therapy
-
[PMID: 24051549]
-
Audemard A, de Raucourt S, Miocque S, Comoz F, Giraud JM, Dreno B, et al. Melanoma-associated retinopathy treated with ipilimumab therapy. Dermatology. 2013;227:146-9. [PMID: 24051549] doi:10.1159/000353408
-
(2013)
Dermatology
, vol.227
, pp. 146-149
-
-
Audemard, A.1
De Raucourt, S.2
Miocque, S.3
Comoz, F.4
Giraud, J.M.5
Dreno, B.6
-
20
-
-
85019547045
-
Vasculitic neuropathy induced by pembrolizumab
-
[PMID: 27864214]
-
Aya F, Ruiz-Esquide V, Viladot M, Font C, Prieto-González S, Prat A, et al. Vasculitic neuropathy induced by pembrolizumab. Ann Oncol. 2017;28:433-4. [PMID: 27864214] doi:10.1093/annonc/mdw613
-
(2017)
Ann Oncol.
, vol.28
, pp. 433-434
-
-
Aya, F.1
Ruiz-Esquide, V.2
Viladot, M.3
Font, C.4
Prieto-González, S.5
Prat, A.6
-
21
-
-
84958985225
-
Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer
-
Bagley SJ, Kosteva JA, Evans TL, Langer CJ. Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer. Cancer Treat Commun. 2016;6:20-3.
-
(2016)
Cancer Treat Commun.
, vol.6
, pp. 20-23
-
-
Bagley, S.J.1
Kosteva, J.A.2
Evans, T.L.3
Langer, C.J.4
-
22
-
-
85015907153
-
Hyperthyroidism followed by worsening primary hypothyroidism in a patient treated with ipilimumab and pembrolizumab
-
Batacchi Z, Alarcon-Casas Wright L. Hyperthyroidism followed by worsening primary hypothyroidism in a patient treated with ipilimumab and pembrolizumab. Thyroid. 2015;25:A215.
-
(2015)
Thyroid.
, vol.25
, pp. A215
-
-
Batacchi, Z.1
Alarcon-Casas Wright, L.2
-
23
-
-
85020929887
-
Nivolumab-induced granulomatous inflammation of the pleura [Letter]
-
[PMID: 28629542]
-
Benn BS, Lombard CM, Krishna G. Nivolumab-induced granulomatous inflammation of the pleura [Letter]. J Thorac Oncol. 2017;12: e100-1. [PMID: 28629542] doi:10.1016/j.jtho.2017.03.006
-
(2017)
J Thorac Oncol.
, vol.12
, pp. e100-e101
-
-
Benn, B.S.1
Lombard, C.M.2
Krishna, G.3
-
24
-
-
84997610273
-
Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis
-
[PMID: 25992290]
-
Bostwick AD, Salama AK, Hanks BA. Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J Immunother Cancer. 2015;3:19. [PMID: 25992290] doi:10.1186/s40425-015-0064-2
-
(2015)
J Immunother Cancer
, vol.3
, pp. 19
-
-
Bostwick, A.D.1
Salama, A.K.2
Hanks, B.A.3
-
25
-
-
84971324112
-
Severe psoriasis flare after anti-programmed death ligand 1 (PD-L1) therapy for metastatic non-small cell lung cancer (NSCLC)
-
[PMID: 27163740]
-
Chia PL, John T. Severe psoriasis flare after anti-programmed death ligand 1 (PD-L1) therapy for metastatic non-small cell lung cancer (NSCLC). J Immunother. 2016;39:202-4. [PMID: 27163740] doi: 10.1097/CJI.0000000000000121
-
(2016)
J Immunother.
, vol.39
, pp. 202-204
-
-
Chia, P.L.1
John, T.2
-
26
-
-
85044402169
-
Granulomatosis with polyangiitis associated with immune checkpoint blockade: Case report and literature review
-
Cusnir I, Solez K, Yacyshyn E. Granulomatosis with polyangiitis associated with immune checkpoint blockade: case report and literature review. J Rheumatol. 2017;44(Suppl 6):950.
-
(2017)
J Rheumatol.
, vol.44
, pp. 950
-
-
Cusnir, I.1
Solez, K.2
Yacyshyn, E.3
-
27
-
-
85019873747
-
Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade [Letter]
-
[PMID: 28514612]
-
Esfahani K, Miller WH Jr. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade [Letter]. N Engl J Med. 2017;376:1989-91. [PMID: 28514612] doi:10.1056/NEJMc1703047
-
(2017)
N Engl J Med.
, vol.376
, pp. 1989-1991
-
-
Esfahani, K.1
Miller, W.H.2
-
28
-
-
84981250350
-
CTLA4 as immunological checkpoint in the development of multiple sclerosis
-
[PMID: 27351142]
-
Gerdes LA, Held K, Beltrán E, Berking C, Prinz JC, Junker A, et al. CTLA4 as immunological checkpoint in the development of multiple sclerosis. Ann Neurol. 2016;80:294-300. [PMID: 27351142] doi:10.1002/ana.24715
-
(2016)
Ann Neurol.
, vol.80
, pp. 294-300
-
-
Gerdes, L.A.1
Held, K.2
Beltrán, E.3
Berking, C.4
Prinz, J.C.5
Junker, A.6
-
29
-
-
84952785505
-
Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma [Letter]
-
[PMID: 25257614]
-
Gettings EJ, Hackett CT, Scott TF. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma [Letter]. Mult Scler. 2015;21:670. [PMID: 25257614] doi:10.1177/1352458514549403
-
(2015)
Mult Scler.
, vol.21
, pp. 670
-
-
Gettings, E.J.1
Hackett, C.T.2
Scott, T.F.3
-
30
-
-
84918517634
-
Ipilimumab in a patient with known Crohn's disease: To give or not to give? [Letter]
-
[PMID: 25154682]
-
Gielisse EA, de Boer NK. Ipilimumab in a patient with known Crohn's disease: to give or not to give? [Letter]. J Crohns Colitis. 2014;8:1742. [PMID: 25154682] doi:10.1016/j.crohns.2014.08.002
-
(2014)
J Crohns Colitis
, vol.8
, pp. 1742
-
-
Gielisse, E.A.1
De Boer, N.K.2
-
31
-
-
85058904959
-
Myasthenic syndrome with pembrolizumab use
-
Hegde U, Chauhan A, Desai N. Myasthenic syndrome with pembrolizumab use. Neurology. 2017;88(Suppl P6.175):1526-632X.
-
(2017)
Neurology.
, vol.88
, pp. 1526X-1632X
-
-
Hegde, U.1
Chauhan, A.2
Desai, N.3
-
32
-
-
84962198249
-
Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy [Letter]
-
[PMID: 25805871]
-
Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy [Letter]. Diabetes Care. 2015;38:e55-7. [PMID: 25805871] doi:10.2337/dc14-2349
-
(2015)
Diabetes Care
, vol.38
, pp. e55-e57
-
-
Hughes, J.1
Vudattu, N.2
Sznol, M.3
Gettinger, S.4
Kluger, H.5
Lupsa, B.6
-
33
-
-
84904553412
-
Kidney injuries related to ipilimumab
-
[PMID: 24687600]
-
Izzedine H, Gueutin V, Gharbi C, Mateus C, Robert C, Routier E, et al. Kidney injuries related to ipilimumab. Invest New Drugs. 2014; 32:769-73. [PMID: 24687600] doi:10.1007/s10637-014-0092-7
-
(2014)
Invest New Drugs
, vol.32
, pp. 769-773
-
-
Izzedine, H.1
Gueutin, V.2
Gharbi, C.3
Mateus, C.4
Robert, C.5
Routier, E.6
-
34
-
-
85044428972
-
A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis
-
Kageyama SI, Yamaguchi S, Ito S, Suehara Y, Saito T, Akaike K, et al. A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis. International Cancer Conference Journal. 2016;5:192-6.
-
(2016)
International Cancer Conference Journal
, vol.5
, pp. 192-196
-
-
Kageyama, S.I.1
Yamaguchi, S.2
Ito, S.3
Suehara, Y.4
Saito, T.5
Akaike, K.6
-
35
-
-
85015837474
-
Ipilimumab-induced colitis in a patient with ulcerative colitis and lung cancer
-
Kamil F, Cohen M, Kumta N, Wan D. Ipilimumab-induced colitis in a patient with ulcerative colitis and lung cancer. Am J Gastroenterol. 2013;108:S404.
-
(2013)
Am J Gastroenterol
, vol.108
, pp. S404
-
-
Kamil, F.1
Cohen, M.2
Kumta, N.3
Wan, D.4
-
36
-
-
84945294851
-
Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma [Letter]
-
[PMID: 26388113]
-
Kato Y, Otsuka A, Miyachi Y, Kabashima K. Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma [Letter]. J Eur Acad Dermatol Venereol. 2016;30:e89-91. [PMID: 26388113] doi:10.1111/jdv.13336
-
(2016)
J Eur Acad Dermatol Venereol.
, vol.30
, pp. e89-e91
-
-
Kato, Y.1
Otsuka, A.2
Miyachi, Y.3
Kabashima, K.4
-
37
-
-
85015411251
-
Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: A case report
-
[PMID: 28315636]
-
Kwatra V, Karanth NV, Priyadarshana K, Charakidis M. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report. J Med Case Rep. 2017;11:73. [PMID: 28315636] doi:10.1186/s13256-017-1229-z
-
(2017)
J Med Case Rep.
, vol.11
, pp. 73
-
-
Kwatra, V.1
Karanth, N.V.2
Priyadarshana, K.3
Charakidis, M.4
-
38
-
-
84977136814
-
Ipilimumab in patients with melanoma and autoimmune disease
-
[PMID: 25349698]
-
Kyi C, Carvajal RD, Wolchok JD, Postow MA. Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer. 2014;2:35. [PMID: 25349698] doi:10.1186/s40425-014-0035-z
-
(2014)
J Immunother Cancer
, vol.2
, pp. 35
-
-
Kyi, C.1
Carvajal, R.D.2
Wolchok, J.D.3
Postow, M.A.4
-
39
-
-
84975078639
-
Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab
-
[PMID: 27065302]
-
Lau KH, Kumar A, Yang IH, Nowak RJ. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve. 2016;54:157-61. [PMID: 27065302] doi:10.1002/mus.25141
-
(2016)
Muscle Nerve.
, vol.54
, pp. 157-161
-
-
Lau, K.H.1
Kumar, A.2
Yang, I.H.3
Nowak, R.J.4
-
40
-
-
85015914196
-
A case of myasthenia gravis exacerbation in a patient with melanoma treated with pembrolizumab
-
Lau KHV, Kumar A, Yang I, Nowak R. A case of myasthenia gravis exacerbation in a patient with melanoma treated with pembrolizumab. Neurology. 2016;86(Suppl P3.138).
-
(2016)
Neurology
, vol.86
-
-
Lau, K.H.V.1
Kumar, A.2
Yang, I.3
Nowak, R.4
-
41
-
-
84994158163
-
Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis
-
[PMID: 27019533]
-
Maeda O, Yokota K, Atsuta N, Katsuno M, Akiyama M, Ando Y. Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci. 2016;78:119-22. [PMID: 27019533]
-
(2016)
Nagoya J Med Sci.
, vol.78
, pp. 119-122
-
-
Maeda, O.1
Yokota, K.2
Atsuta, N.3
Katsuno, M.4
Akiyama, M.5
Ando, Y.6
-
42
-
-
84954554294
-
Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma
-
[PMID: 26270860]
-
Matsumura N, Ohtsuka M, Kikuchi N, Yamamoto T. Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma. Acta Derm Venereol. 2016;96:259-60. [PMID: 26270860] doi:10.2340/00015555-2212
-
(2016)
Acta Derm Venereol.
, vol.96
, pp. 259-260
-
-
Matsumura, N.1
Ohtsuka, M.2
Kikuchi, N.3
Yamamoto, T.4
-
43
-
-
84961942697
-
Successful anti-PD-1 antibody treatment in a metastatic melanoma patient with known severe autoimmune disease
-
[PMID: 27023060]
-
Maul LV, Weichenthal M, Kähler KC, Hauschild A. Successful anti-PD-1 antibody treatment in a metastatic melanoma patient with known severe autoimmune disease. J Immunother. 2016;39:188-90. [PMID: 27023060] doi:10.1097/CJI.0000000000000118
-
(2016)
J Immunother.
, vol.39
, pp. 188-190
-
-
Maul, L.V.1
Weichenthal, M.2
Kähler, K.C.3
Hauschild, A.4
-
44
-
-
84956840392
-
Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab
-
[PMID: 26198822]
-
Narita T, Oiso N, Taketomo Y, Okahashi K, Yamauchi K, Sato M, et al. Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab. J Dermatol. 2016;43:210-4. [PMID: 26198822] doi:10.1111/1346-8138.13028
-
(2016)
J Dermatol.
, vol.43
, pp. 210-214
-
-
Narita, T.1
Oiso, N.2
Taketomo, Y.3
Okahashi, K.4
Yamauchi, K.5
Sato, M.6
-
45
-
-
84997794621
-
Antitumor activity of nivolumab on hemodialysis after renal allograft rejection
-
[PMID: 27777773]
-
Ong M, Ibrahim AM, Bourassa-Blanchette S, Canil C, Fairhead T, Knoll G. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection. J Immunother Cancer. 2016;4:64. [PMID: 27777773]
-
(2016)
J Immunother Cancer
, vol.4
, pp. 64
-
-
Ong, M.1
Ibrahim, A.M.2
Bourassa-Blanchette, S.3
Canil, C.4
Fairhead, T.5
Knoll, G.6
-
46
-
-
84916205029
-
Successful treatment with ipilimumab and interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease
-
[PMID: 25227926]
-
Pedersen M, Andersen R, Nørgaard P, Jacobsen S, Thielsen P, Thor Straten P, et al. Successful treatment with ipilimumab and interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol Immunother. 2014;63: 1341-6. [PMID: 25227926] doi:10.1007/s00262-014-1607-y
-
(2014)
Cancer Immunol Immunother
, vol.63
, pp. 1341-1346
-
-
Pedersen, M.1
Andersen, R.2
Nørgaard, P.3
Jacobsen, S.4
Thielsen, P.5
Thor Straten, P.6
-
47
-
-
85050580151
-
Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: A report of 2 patient cases
-
2324709616674316 [PMID: 27826593]
-
Phadke SD, Ghabour R, Swick BL, Swenson A, Milhem M, Zakharia Y. Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: a report of 2 patient cases. J Investig Med High Impact Case Rep. 2016;4:2324709616674316. [PMID: 27826593]
-
(2016)
J Investig Med High Impact Case Rep.
, vol.4
-
-
Phadke, S.D.1
Ghabour, R.2
Swick, B.L.3
Swenson, A.4
Milhem, M.5
Zakharia, Y.6
-
48
-
-
85016348948
-
Induction of muscular sarcoidosis in a metastastic melanoma patient treated with ipilimumab
-
Plachouri KM, Mohr M, Sunderkotter C, Weishaupt C. Induction of muscular sarcoidosis in a metastastic melanoma patient treated with ipilimumab. J Dtsch Dermatol Ges. 2012;10:861.
-
(2012)
J Dtsch Dermatol Ges.
, vol.10
, pp. 861
-
-
Plachouri, K.M.1
Mohr, M.2
Sunderkotter, C.3
Weishaupt, C.4
-
49
-
-
85044433170
-
The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis
-
[PMID: 28817445]
-
Puri A, Homsi J. The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis. Melanoma Res. 2017;27:519-23. [PMID: 28817445] doi:10.1097/CMR.0000000000000387
-
(2017)
Melanoma Res.
, vol.27
, pp. 519-523
-
-
Puri, A.1
Homsi, J.2
-
50
-
-
84997235698
-
Chorioretinal lesions in a case of melanoma-associated retinopathy treated with pembrolizumab
-
[PMID: 27540851]
-
Roberts P, Fishman GA, Joshi K, Jampol LM. Chorioretinal lesions in a case of melanoma-associated retinopathy treated with pembrolizumab. JAMA Ophthalmol. 2016;134:1184-8. [PMID: 27540851] doi:10.1001/jamaophthalmol.2016.2944
-
(2016)
JAMA Ophthalmol
, vol.134
, pp. 1184-1188
-
-
Roberts, P.1
Fishman, G.A.2
Joshi, K.3
Jampol, L.M.4
-
51
-
-
85044411787
-
Treatment of Merkel cell carcinoma with pembrolizumab in a patient with psoriasis and psoriatic arthritis
-
Roche L, Murphy M, Power D. Treatment of Merkel cell carcinoma with pembrolizumab in a patient with psoriasis and psoriatic arthritis. Br J Dermatol. 2017;177(Suppl 1):140-54.
-
(2017)
Br J Dermatol.
, vol.177
, pp. 140-154
-
-
Roche, L.1
Murphy, M.2
Power, D.3
-
53
-
-
84974846127
-
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
-
[PMID: 26951628]
-
Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol. 2016;27:1135-7. [PMID: 26951628] doi:10.1093/annonc/mdw130
-
(2016)
Ann Oncol.
, vol.27
, pp. 1135-1137
-
-
Spain, L.1
Higgins, R.2
Gopalakrishnan, K.3
Turajlic, S.4
Gore, M.5
Larkin, J.6
-
54
-
-
84984920567
-
Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: A case report
-
[PMID: 27595932]
-
Uemura M, Trinh VA, Haymaker C, Jackson N, Kim DW, Allison JP, et al. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. J Hematol Oncol. 2016;9:81. [PMID: 27595932] doi:10.1186/s13045-016-0309-7
-
(2016)
J Hematol Oncol.
, vol.9
, pp. 81
-
-
Uemura, M.1
Trinh, V.A.2
Haymaker, C.3
Jackson, N.4
Kim, D.W.5
Allison, J.P.6
-
55
-
-
85016355628
-
Muscular sarcoidosis in a metastatic melanoma patient treated with ipilimumab
-
Weishaupt C, Mohr M, Sunderkotter C. Muscular sarcoidosis in a metastatic melanoma patient treated with ipilimumab. J Dtsch Dermatol Ges. 2012;10:683.
-
(2012)
J Dtsch Dermatol Ges.
, vol.10
, pp. 683
-
-
Weishaupt, C.1
Mohr, M.2
Sunderkotter, C.3
-
56
-
-
84982171125
-
Myasthenia gravis exacerbation associated with pembrolizumab
-
[PMID: 26802533]
-
Zhu J, Li Y. Myasthenia gravis exacerbation associated with pembrolizumab. Muscle Nerve. 2016;54:506-7. [PMID: 26802533] doi:10.1002/mus.25055
-
(2016)
Muscle Nerve.
, vol.54
, pp. 506-507
-
-
Zhu, J.1
Li, Y.2
-
57
-
-
85016342140
-
Anti-CTLA-4 antibody therapy causing autoimmune hypophysitis in a patient with a longstanding history of Hashimotos's thyroiditis
-
Zmeili O, Samantray J. Anti-CTLA-4 antibody therapy causing autoimmune hypophysitis in a patient with a longstanding history of Hashimotos's thyroiditis. Endocr Rev. 2013;1.
-
(2013)
Endocr Rev.
, pp. 1
-
-
Zmeili, O.1
Samantray, J.2
-
58
-
-
85012893091
-
Vedolizumab treatment for immune checkpoint inhibitorinduced enterocolitis
-
[PMID: 28204866]
-
Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, et al. Vedolizumab treatment for immune checkpoint inhibitorinduced enterocolitis. Cancer Immunol Immunother. 2017;66:581-92. [PMID: 28204866] doi:10.1007/s00262-017-1962-6
-
(2017)
Cancer Immunol Immunother.
, vol.66
, pp. 581-592
-
-
Bergqvist, V.1
Hertervig, E.2
Gedeon, P.3
Kopljar, M.4
Griph, H.5
Kinhult, S.6
-
59
-
-
84998706924
-
Anti-PD1-induced psoriasis: A study of 21 patients [Letter]
-
Groupe de Recherche sur le Psoriasis and the Groupe Cancérologie Cutanée of the Société Française de Dermatologie the GEM Resopso, Apsoderm and the Groupe Français de Pneumo-Cancérologie [PMID: 27739129]
-
Bonigen J, Raynaud-Donzel C, Hureaux J, Kramkimel N, Blom A, Jeudy G, et al; Groupe de Recherche sur le Psoriasis and the Groupe Cancérologie Cutanée of the Société Française de Dermatologie the GEM Resopso, Apsoderm and the Groupe Français de Pneumo-Cancérologie. Anti-PD1-induced psoriasis: a study of 21 patients [Letter]. J Eur Acad Dermatol Venereol. 2017;31:e254-7. [PMID: 27739129] doi:10.1111/jdv.14011
-
(2017)
J Eur Acad Dermatol Venereol.
, vol.31
, pp. e254-e257
-
-
Bonigen, J.1
Raynaud-Donzel, C.2
Hureaux, J.3
Kramkimel, N.4
Blom, A.5
Jeudy, G.6
-
60
-
-
85015958229
-
Rheumatic immune-related adverse events of checkpoint therapy for cancer: Case series of a new nosological entity
-
[PMID: 28405474]
-
Calabrese C, Kirchner E, Kontzias K, Velcheti V, Calabrese LH. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017;3: e000412. [PMID: 28405474] doi:10.1136/rmdopen-2016-000412
-
(2017)
RMD Open
, vol.3
, pp. e000412
-
-
Calabrese, C.1
Kirchner, E.2
Kontzias, K.3
Velcheti, V.4
Calabrese, L.H.5
-
61
-
-
84974824082
-
The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma [Letter]
-
[PMID: 26861600]
-
Lee B, Wong A, Kee D, Neeson P, Shackleton M, McArthur G, et al. The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma [Letter]. Ann Oncol. 2016;27:1174-7. [PMID: 26861600] doi:10.1093/annonc/mdw056
-
(2016)
Ann Oncol.
, vol.27
, pp. 1174-1177
-
-
Lee, B.1
Wong, A.2
Kee, D.3
Neeson, P.4
Shackleton, M.5
McArthur, G.6
-
62
-
-
85029681029
-
PD-1 inhibitorassociated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation-report of 4 cases
-
[PMID: 28753231]
-
Chou S, Zhao C, Hwang SJE, Fernandez-Penas P. PD-1 inhibitorassociated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation-report of 4 cases. J Cutan Pathol. 2017;44: 851-6. [PMID: 28753231] doi:10.1111/cup.13013
-
(2017)
J Cutan Pathol.
, vol.44
, pp. 851-856
-
-
Chou, S.1
Zhao, C.2
Hwang, S.J.E.3
Fernandez-Penas, P.4
-
63
-
-
85013175346
-
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
-
German Dermatooncology Group (DeCOG) [PMID: 28214654]
-
Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, et al; German Dermatooncology Group (DeCOG). Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer. 2017;75:24-32. [PMID: 28214654] doi: 10.1016/j.ejca.2016.12.038
-
(2017)
Eur J Cancer
, vol.75
, pp. 24-32
-
-
Gutzmer, R.1
Koop, A.2
Meier, F.3
Hassel, J.C.4
Terheyden, P.5
Zimmer, L.6
-
64
-
-
84947703441
-
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
-
Johnson DB, Khushalani NI, Puzanov I, Mudigonda T, Kaufman H, Sosman JA, et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. J Clin Oncol. 2015; 33(Suppl 1):9019.
-
(2015)
J Clin Oncol.
, vol.33
, pp. 9019
-
-
Johnson, D.B.1
Khushalani, N.I.2
Puzanov, I.3
Mudigonda, T.4
Kaufman, H.5
Sosman, J.A.6
-
65
-
-
85003054266
-
Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders
-
[PMID: 26633184]
-
Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2:234-40. [PMID: 26633184] doi:10.1001/jamaoncol.2015.4368.
-
(2016)
JAMA Oncol.
, vol.2
, pp. 234-240
-
-
Johnson, D.B.1
Sullivan, R.J.2
Ott, P.A.3
Carlino, M.S.4
Khushalani, N.I.5
Ye, F.6
-
66
-
-
85021128995
-
Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/antiprogrammed cell death-ligand 1 agents: A single-centre pharmacovigilance database analysis
-
[PMID: 28646772]
-
Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, et al. Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/antiprogrammed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer. 2017;82:34-44. [PMID: 28646772] doi:10.1016/j.ejca.2017.05.032
-
(2017)
Eur J Cancer
, vol.82
, pp. 34-44
-
-
Le Burel, S.1
Champiat, S.2
Mateus, C.3
Marabelle, A.4
Michot, J.M.5
Robert, C.6
-
67
-
-
85044424850
-
Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy [Letter]
-
[PMID: 28242618]
-
Le Burel S, Champiat S, Routier E, Aspeslagh S, Albiges L, Szwebel TA, et al. Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy [Letter]. Ann Rheum Dis. 2017. [PMID: 28242618] doi:10.1136/annrheumdis-2016-210820
-
(2017)
Ann Rheum Dis.
-
-
Le Burel, S.1
Champiat, S.2
Routier, E.3
Aspeslagh, S.4
Albiges, L.5
Szwebel, T.A.6
-
68
-
-
84892866206
-
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma
-
[PMID: 24145345]
-
Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J Clin Oncol. 2013;31:4311-8. [PMID: 24145345] doi:10.1200/JCO.2013.51.4802
-
(2013)
J Clin Oncol.
, vol.31
, pp. 4311-4318
-
-
Weber, J.S.1
Kudchadkar, R.R.2
Yu, B.3
Gallenstein, D.4
Horak, C.E.5
Inzunza, H.D.6
-
69
-
-
4444354041
-
Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus
-
[PMID: 15138458]
-
Barreto M, Santos E, Ferreira R, Fesel C, Fontes MF, Pereira C, et al. Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet. 2004;12:620-6. [PMID: 15138458]
-
(2004)
Eur J Hum Genet.
, vol.12
, pp. 620-626
-
-
Barreto, M.1
Santos, E.2
Ferreira, R.3
Fesel, C.4
Fontes, M.F.5
Pereira, C.6
-
70
-
-
84939892080
-
Meta-analysis of genetic polymorphisms in programmed cell death 1. Associations with rheumatoid arthritis, ankylosing spondylitis, and type 1 diabetes susceptibility
-
[PMID: 24942602]
-
Lee YH, Bae SC, Kim JH, Song GG. Meta-analysis of genetic polymorphisms in programmed cell death 1. Associations with rheumatoid arthritis, ankylosing spondylitis, and type 1 diabetes susceptibility. Z Rheumatol. 2015;74:230-9. [PMID: 24942602] doi:10.1007/s00393-014-1415-y
-
(2015)
Z Rheumatol.
, vol.74
, pp. 230-239
-
-
Lee, Y.H.1
Bae, S.C.2
Kim, J.H.3
Song, G.G.4
-
71
-
-
84896548089
-
CTLA-4 polymorphisms and susceptibility to inflammatory bowel disease: A meta-analysis
-
[PMID:24530750]
-
Lee YH, Kim JH, Seo YH, Choi SJ, Ji JD, Song GG. CTLA-4 polymorphisms and susceptibility to inflammatory bowel disease: a meta-analysis. Hum Immunol.2014;75:414-21.[PMID:24530750]doi: 10.1016/j.humimm.2014.02.020
-
(2014)
Hum Immunol.
, vol.75
, pp. 414-421
-
-
Lee, Y.H.1
Kim, J.H.2
Seo, Y.H.3
Choi, S.J.4
Ji, J.D.5
Song, G.G.6
-
72
-
-
62749182367
-
Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: A meta-analysis
-
[PMID: 19074163]
-
Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: a meta-analysis. Lupus. 2009;18:9-15. [PMID: 19074163] doi: 10.1177/0961203308093923
-
(2009)
Lupus.
, vol.18
, pp. 9-15
-
-
Lee, Y.H.1
Woo, J.H.2
Choi, S.J.3
Ji, J.D.4
Song, G.G.5
-
73
-
-
84910101471
-
The effect of CTLA-4 A49G polymorphism on rheumatoid arthritis risk: A meta-analysis
-
[PMID: 25128482]
-
Li G, Shi F, Liu J, Li Y. The effect of CTLA-4 A49G polymorphism on rheumatoid arthritis risk: a meta-analysis. Diagn Pathol. 2014;9: 157. [PMID: 25128482] doi:10.1186/s13000-014-0157-0
-
(2014)
Diagn Pathol.
, vol.9
, pp. 157
-
-
Li, G.1
Shi, F.2
Liu, J.3
Li, Y.4
-
74
-
-
62149115181
-
Association between the PD1.3A/G polymorphism of the PDCD1 gene and systemic lupus erythematosus in European populations: A meta-analysis
-
[PMID: 19220647]
-
Liu JL, Zhang FY, Liang YH, Xiao FL, Zhang SQ, Cheng YL, et al. Association between the PD1.3A/G polymorphism of the PDCD1 gene and systemic lupus erythematosus in European populations: a meta-analysis. J Eur Acad Dermatol Venereol. 2009;23:425-32. [PMID: 19220647] doi:10.1111/j.1468-3083.2009.03087.x
-
(2009)
J Eur Acad Dermatol Venereol.
, vol.23
, pp. 425-432
-
-
Liu, J.L.1
Zhang, F.Y.2
Liang, Y.H.3
Xiao, F.L.4
Zhang, S.Q.5
Cheng, Y.L.6
-
75
-
-
47249153181
-
CTLA-4: A key regulatory point in the control of autoimmune disease
-
[PMID: 18613834]
-
Scalapino KJ, Daikh DI. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev. 2008;223:143-55. [PMID: 18613834] doi:10.1111/j.1600-065X.2008.00639.x
-
(2008)
Immunol Rev.
, vol.223
, pp. 143-155
-
-
Scalapino, K.J.1
Daikh, D.I.2
-
76
-
-
85016830728
-
The association between CTLA-4 (+49 A/G) polymorphism and susceptibility to ankylosing spondylitis: A meta-analysis
-
[PMID: 26176417]
-
Wu J, Zhang L, Zhou Y. The association between CTLA-4 (+49 A/G) polymorphism and susceptibility to ankylosing spondylitis: a meta-analysis. Int J Rheum Dis. 2016;19:1237-43. [PMID: 26176417] doi:10.1111/1756-185X.12705
-
(2016)
Int J Rheum Dis.
, vol.19
, pp. 1237-1243
-
-
Wu, J.1
Zhang, L.2
Zhou, Y.3
-
77
-
-
85030215805
-
Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature
-
[PMID: 27998041]
-
Cappelli LC, Gutierrez AK, Bingham CO 3rd, Shah AA. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res (Hoboken). 2017;69:1751-63. [PMID: 27998041] doi:10.1002/acr.23177
-
(2017)
Arthritis Care Res (Hoboken)
, vol.69
, pp. 1751-1763
-
-
Cappelli, L.C.1
Gutierrez, A.K.2
Bingham, C.O.3
Shah, A.A.4
-
78
-
-
85019333926
-
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
-
[PMID: 27687304]
-
Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28:368-76. [PMID: 27687304] doi: 10.1093/annonc/mdw443
-
(2017)
Ann Oncol.
, vol.28
, pp. 368-376
-
-
Menzies, A.M.1
Johnson, D.B.2
Ramanujam, S.3
Atkinson, V.G.4
Wong, A.N.M.5
Park, J.J.6
|